Imperative Care’s Zoom Stroke System Studied in M2 Occlusions

July 16, 2025—Imperative Care, Inc. announced findings from a subanalysis of patients with M2 occlusions enrolled in the Imperative Trial treated with the company’s Zoom stroke system. The data were presented by Justin Mascitelli, MD, in a late-breaking abstract at SNIS 2025, the Society of NeuroInterventional Surgery’s annual meeting. Dr. Mascitelli is from UT Health San Antonio in San Antonio, Texas.

According to the company, patients in the subanalysis (n = 65) had a median age of 69 years and presented with a median National Institutes of Health Stroke Scale score of 13.

As outlined in Imperative Care’s press release, the results demonstrated the following:

• An 88% core-lab adjudicated rate of final modified treatment in cerebral infarction (mTICI) ≥ 2B reperfusion
• A 56% modified Rankin Scale (mRS) score of 0-1, and a 62% mRS score of 0-2 at 90 days
• A symptomatic intracranial hemorrhage rate of 1.5% (1/65), an all-cause mortality rate of 4.6% (3/65), and an all-intracranial hemorrhage rate of 18.5% (12/65)

“These data suggest that excellent safety and clinical outcomes can be achieved with aspiration thrombectomy in patients with M2 occlusions,” commented Dr. Mascitelli in the company’s press release. “The clinical community has important questions around the impact of treating medium vessel occlusions and distal medium vessel occlusion patients, given the ESCAPE-MeVO and DISTAL trial data evaluating stent retriever and the best medical-based treatments. It’s critical that this topic be further explored with evidence-generating studies on aspiration specifically, which I believe will undoubtedly move the field—and most importantly, patient outcomes—forward.”

In 2025, ESCAPE-MeVO was published by Mayank Goyal, MD, et al (N Engl J Med. 2025;392:1385-1395), and DISTAL was published by Marios Psychogios, MD, et al (N Engl J Med. 2025;392:1374-1384).

Imperative Care also noted that it will fund an investigator-initiated, randomized clinical trial comparing continuous dual aspiration thrombectomy (CDAT) with the Zoom stroke system plus best medical treatment versus best medical treatment alone for M2 vessel occlusions in stroke patients. This trial will investigate an aspiration approach specifically for M2 occlusions to evaluate the potential impact of aspiration thrombectomy on these patients.

The company first announced the initiative in April 2025. The company launched its Zoom DuoPort technology for the Zoom stroke system that allows CDAT with two Zoom aspiration catheters simultaneously from a single vacuum source.

In January 2025, Imperative Care announced that it received FDA 510(k) clearance of the Zoom system.